Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Changma Xifeng Pian
- Development stage
- Unknown
- Lead developer
- Guang'anmen Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Changma Xifeng Pian (CMXF) is a traditional Chinese medicine (TCM) multi-herb formulation developed for the treatment of Tourette syndrome (TS) and other pediatric tic disorders. It is a multi-component herbal tablet containing at least 21 identified chemical constituents, including gallic acid, gastrodin, catechin, sibiricose A3, paeoniflorin, parishin B, and tenuifoliside B. The formulation is designed to calm the liver, suppress wind, resolve phlegm, and restore visceral balance according to TCM principles. Pharmacologically, it acts on multiple biological targets, including the androgen receptor (AR), metabotropic glutamate receptor 5 (GRM5), hepatocyte growth factor receptor (MET), and serotonin receptor 2A (HTR2A). It has been evaluated in clinical trials, often in combination with Western medicines like tiapride, for the management of moderate tic disorders in children.
- Brand names
- Changma Xifeng PianChangma Xifeng Tablet
- Other names
- ChangMaXiFeng Pian菖麻熄风片
02
Targets
CNR1 (Cannabinoid receptor 1)GRM5 (Metabotropic glutamate receptor 5)HTR2A (5-hydroxytryptamine receptor 2A)MET (Mesenchymal-epithelial transition factor receptor)PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)TOP1 (DNA Topoisomerase I)HTR2A (Serotonin receptor 5-HT2A)AR (Adrenergic receptors)RORA (Retinoic acid-related orphan receptor alpha)
Beyond the preview
Go deeper on Changma Xifeng Pian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Changma Xifeng Pian.